Organovo Holdings is a 3D biology company focused on delivering bioprinting technology and creating tissue on demand for research and medical applications. The company’s NovoGen 3D bioprinting technology is a platform that works across all tissue and cell types. ONVO assists pharmaceutical partners in developing human biological disease models in 3D that enable therapeutic drug discovery and development. The company’s bioprinting technology can also be developed to create surgical tissues direct therapy. For more information visit the company’s Web site at: www.organovo.com
Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.
Let us hear your thoughts below: